Financial Performance - The company's total revenue for 2022 was ¥674,905,595.63, a decrease of 59.71% compared to ¥1,675,320,034.94 in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥163,686,641.34, down 69.43% from ¥535,415,008.89 in the previous year[27]. - The operating cash flow net amount for 2022 was ¥84,264,654.04, representing an 86.88% decline from ¥642,075,356.24 in 2021[27]. - Basic earnings per share for 2022 were ¥0.82, a decrease of 76.77% compared to ¥3.53 in 2021[27]. - The company reported a significant decline in net profit due to a sharp drop in erythritol prices caused by weak terminal demand and industry expansion[63]. - The company's revenue for erythritol in 2022 was approximately ¥574.74 million, a decrease of 63.33% compared to ¥1.57 billion in 2021, with a gross margin of 10.50%[57]. - The company's domestic revenue fell by 66.79% to CNY 214.49 million, while international revenue decreased by 55.28% to CNY 460.42 million[80]. - The comprehensive gross margin in 2021 was 41.99%, but it faced a substantial decline in 2022 due to reduced sales volume and price drops[137]. Market Conditions - The sales revenue of the company's products declined due to economic downturn and weak consumer demand, leading to a decrease in order volume[4]. - The market price of erythritol significantly dropped, compressing the profit margins for industry players[4]. - The functional sugar industry, particularly erythritol, faced increased competition in 2022, leading to a supply surplus and a significant drop in prices, impacting profitability[43]. - The demand for functional sugars is expected to grow due to rising health awareness and changing consumer preferences towards low-calorie and sugar-free products[45]. - The company reported a significant loss from fair value changes of trading financial assets, amounting to ¥-13,219,241.96 in 2022, compared to a gain of ¥256,700.00 in 2021[34]. Dividends and Shareholder Returns - The company plans to distribute a cash dividend of 7 RMB per 10 shares to all shareholders, based on a total of 202,325,700 shares[6]. - The total cash dividend amount (including other methods) is 141,627,990.00 CNY, which accounts for 100% of the total distributable profit[195]. - The company plans to distribute a cash dividend of 7.00 CNY per 10 shares for the year 2022, totaling 141,627,990.00 CNY, with no stock dividends or capital reserve transfers[198]. Research and Development - The company has a strong focus on R&D for functional sugars and new sweeteners, having overcome various technical challenges in the erythritol production process over the past decade[48]. - The company aims to enhance its research and development capabilities by collaborating with leading food fermentation research institutions[129]. - The company is implementing a product development strategy of "one generation on the market, one in research, and one in reserve" to ensure a steady pipeline of new products[128]. - The company has invested in a wholly-owned R&D subsidiary to enhance product development and technological innovation, focusing on functional sugars and other new products[78]. - The company has completed the development of alulose preparation technology, achieving a purity of over 95%[95]. Production and Operations - The company operates in the functional sugar sector, which is supported by national policies promoting health and nutrition, creating a favorable macro market environment[42]. - The company benefits from its location in Shandong Province, a key area for corn processing, ensuring stable raw material supply for erythritol production[46]. - The erythritol production process is fermentation-based, with stable year-round supply of necessary raw materials, minimizing seasonal production disruptions[46]. - The company has a production capacity of 135,000 tons of erythritol, making it the largest producer globally[74]. - The production line for allulose with a capacity of 2,000 tons/year was completed and put into operation by the end of 2022, with remaining capacity expected to be operational this year[128]. Strategic Initiatives - The company plans to launch a new brand, "Yuan Sheng Tian," in small packaging to expand its market reach from B2B to B2C, enhancing brand awareness and market influence[54]. - The company is focusing on developing new products such as steviol glycosides and hyaluronic acid to diversify its product offerings[132]. - The company aims to achieve a fermentation reaction cycle of no more than 24 hours and a yield of no less than 95% in its glucose acid production technology[96]. - The company is actively expanding its customer base by developing new products and targeting small and medium enterprises[139]. - The company is in the process of establishing a new project for the production of 20,000 tons of aloin sugar, with an investment of 50.48 million yuan[109]. Governance and Management - The company maintains a strict governance structure, ensuring no undisclosed information is provided to major shareholders or actual controllers, thus protecting minority shareholders' interests[150]. - The company has established a comprehensive internal audit system, enhancing operational management and risk control, which supports the achievement of business objectives[153]. - The company has a board of directors with members having extensive backgrounds in various industries, contributing to its strategic direction[165]. - The management team is committed to improving operational efficiency and maximizing shareholder value through strategic planning[165]. - The company has established an effective internal control system to enhance decision-making efficiency and safeguard asset security[200]. Future Outlook - In 2023, the company aims to strengthen its market position in erythritol and develop competitive functional sugars, targeting special medical foods, cosmetics, and drug delivery systems[127]. - The company has set a future outlook with a revenue target of 1.5 billion RMB for the next fiscal year, indicating a projected growth of 25%[171]. - The company plans to enhance its digital marketing efforts, increasing the budget by 40% to improve customer engagement and brand awareness[171]. - The company is investing 30 million RMB in research and development for innovative technologies in the bioengineering sector[171]. - The company is actively monitoring market trends to adapt its strategies accordingly and maintain competitive advantage[165].

Financial Performance - The company's revenue for the first half of 2023 was ¥235.31 million, a decrease of 48.54% compared to ¥457.28 million in the same period last year[26]. - The net profit attributable to shareholders was ¥33.32 million, down 72.04% from ¥119.18 million year-on-year[26]. - The net cash flow from operating activities was ¥245.78 thousand, a significant decline of 99.24% compared to ¥32.36 million in the previous year[26]. - Basic and diluted earnings per share were both ¥0.16, representing a decrease of 73.77% from ¥0.61 in the same period last year[26]. - The gross profit margin for the overall business decreased to 21.30% from 34.69% year-on-year, indicating a significant decline in profitability[60]. - The revenue from erythritol products dropped by 45.87% year-on-year, reflecting a significant decline in market demand and pricing pressure[59]. - The company reported a 60.19% increase in revenue from yeast powder, with a gross profit margin of 60.29%[59]. - The company's total revenue for the first half of 2023 was CNY 235,313,762, a slight increase of 0.12% compared to CNY 235,035,340 in the same period of 2022[59]. - The comprehensive gross profit margin for 2021, 2022, and the first half of 2023 was 41.99%, 14.06%, and 0.12% respectively, indicating significant volatility[119]. Market and Industry Trends - The functional sugar market has seen a surge in demand due to the rising trend of sugar reduction, with erythritol becoming a widely used sweetener across various sectors[35]. - The company operates in the functional sugar industry, focusing on the research, production, and sales of products like erythritol and allulose[34]. - The company anticipates a gradual stabilization of the erythritol market as some new entrants exit due to profit margin pressures, leading to a more balanced supply-demand relationship[37]. - Recent government policies support the functional sugar industry, promoting health-conscious consumption and encouraging the use of low-sugar alternatives[39]. - The "Healthy China 2030" initiative emphasizes the importance of health and nutrition, which aligns with the company's product offerings[39]. - The global trend towards low-calorie and sugar-free diets is accelerating, with erythritol positioned as a key ingredient in this market shift[43]. - The sugar-free beverage market in China is expected to exceed RMB 27.66 billion by 2027, with an annual growth rate of over 10% from 2023 to 2027[43]. Operational Efficiency and Innovation - The company is committed to innovation in product development to meet the evolving consumer preferences for healthier options[35]. - The company has developed proprietary technology that increases the purity of erythritol extraction from below 50% to over 80%[68]. - The company plans to continue optimizing its fermentation and extraction processes to enhance production efficiency and reduce costs[68]. - The company has implemented an integrated ERP and automation system to enhance production efficiency and reduce costs, leading to a decrease in frontline production staff[70]. - The company is currently developing projects for the production of 50,000 tons of erythritol and is in the process of constructing a biomass energy project[90]. Corporate Governance and Compliance - The board of directors confirmed the accuracy and completeness of the financial report, ensuring no false statements or omissions[3]. - The company has established a clear framework for share management to maintain investor confidence and market stability[140]. - The company guarantees that the content of its initial public offering prospectus is true, accurate, and complete, with no false records or misleading statements[148]. - The company has committed to enhancing its core competitiveness and sustainable development capabilities through effective use of the raised funds[146]. - The company emphasizes compliance with legal and regulatory requirements during the stock purchase process[144]. Shareholder Relations and Profit Distribution - The company reported a cash dividend of RMB 7.00 per 10 shares will be distributed to all shareholders, totaling RMB 141.63 million, with no stock dividends or capital reserve transfers[168]. - The company has outlined a three-year dividend return plan for shareholders post-listing to ensure reasonable and stable investment returns[146]. - The company plans to improve its profit distribution policy to enhance investor returns, particularly focusing on independent directors and minority shareholders' opinions[146]. - The company will publicly explain any failure to execute the profit distribution policy and apologize to shareholders and the public[148]. Risk Management - The company is facing intensified competition in the erythritol industry due to increased market supply and changing customer demand, which may impact sales and profitability[112]. - The company has established long-term supply contracts with some customers that include pricing mechanisms to mitigate raw material cost fluctuations[115]. - The company is monitoring political and trade policy changes in key export regions to manage risks associated with international sales[116]. - The company aims to enhance cost management through material substitution, automation, and production efficiency improvements to stabilize gross profit margins[119]. Environmental and Social Responsibility - The company strictly adheres to the Environmental Protection Law of the People's Republic of China and has established an environmental management system, ensuring compliance with national environmental regulations[133]. - The company has implemented effective measures to reduce carbon emissions, including the construction of a solar photovoltaic power station and upgrading manufacturing equipment[133]. - The company emphasizes social responsibility, integrating corporate and social benefits while achieving its business goals[134]. - The company protects employee rights by adhering to labor laws and providing social insurance, enhancing employee welfare and safety[136].

证券代码：301206 证券简称：三元生物 公告编号：2023-039 山东三元生物科技股份有限公司 关于首次公开发行前已发行的部分股份解除限售并上市 流通的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意山东三元生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2021】4073 号）同意注册，公司公开发 行人民币普通股（A 股）33,721,000 股，并于 2022 年 2 月 10 日在深圳证券交易 所创业板上市交易。首次公开发行股票完成后，公司总股本由 101,162,800 股变 更为 134,883,800 股，其中有限售条件流通股为 102,902,271 股，占发行后总股本 的比例 76.29%，无限售条件流通股为 31,981,529 股，占发行后总股本的比例为 23.71%。 1 / 5 （二）上市后股份变动情况 特别提示： 1、本次上市流通的限售股为山东三元生物科技股份有限公司（以下简称"公 司"或"三元生物"）首次公开发行前已发行的股份。 2、本次解除限售股 ...

本次申请解除股份限售的股东共计 7 名，包括李德春、程保华、曹颖、郑海 军、韦红夫、于俊玲、崔鲁朋 7 位个人股东。 本次申请解除股份限售的股东在《首次公开发行股票并在创业板上市招股说 明书》和《首次公开发行股票并在创业板上市之上市公告书》做出的承诺具体情 况如下： 中信建投证券股份有限公司关于山东三元生物科技股份有限公司 首次公开发行前已发行的部分股份解除限售并上市流通的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐机构"） 作为山东三元生物科技股份有限公司（以下简称"三元生物"或"公司"）首次 公开发行股票并在创业板上市持续督导阶段的保荐机构，根据《证券发行上市保 荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、法规和规 范性文件的规定，对三元生物首次公开发行前已发行的部分股份解除限售并上市 流通事项进行了审慎核查，核查意见如： 一、首次公开发行股份及变动情况 经中国证券监督管理委员会《关于同意山东三元生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2021】4073 号）同意注 ...

证券代码：301206 证券简称：三元生物 山东三元生物科技股份有限公司 2022 年度业绩说明会投资者关系活动记录表 编号：2023-002 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 及人员姓名 采用网络远程方式进行，面向全体投资者 时间 2023 年 5 月 12 日 15:00-17:00 地点 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 主持人：三元生物 董事长、代董秘：聂在建 公司接待人员 总经理：程保华 姓名 财务总监：于俊玲 独立董事：赵春海 保荐代表人：陆丹君 公司于2023年5月12日(星期五)下午15:00-17:00，在互动易平台-云 访谈栏目（ http://irm.cninfo.com.cn）举办了2022年度业绩说明会，并就 投资者在本次说明会中提出的相关问题进行了回复，主要内容如下: 投资者关系活动 主要内容介绍 1、元气森林开始没有采购三元生物赤藓糖醇具体时间是哪年哪 月？ 答：尊敬的投资者，您 ...

Financial Performance - The company's operating revenue for 2022 was ¥674,905,595.63, a decrease of 59.71% compared to ¥1,675,320,034.94 in 2021[27]. - The net profit attributable to shareholders for 2022 was ¥163,686,641.34, down 69.43% from ¥535,415,008.89 in the previous year[27]. - The cash flow from operating activities for 2022 was ¥84,264,654.04, representing an 86.88% decline from ¥642,075,356.24 in 2021[27]. - Basic earnings per share for 2022 were ¥0.82, a decrease of 76.77% compared to ¥3.53 in 2021[27]. - The company reported a quarterly revenue of ¥272,598,107.02 in Q1 2022, which decreased to ¥111,541,943.95 in Q4 2022[29]. - The net profit attributable to shareholders in Q4 2022 was ¥12,530,699.56, significantly lower than ¥62,765,994.16 in Q1 2022[29]. - The company experienced a significant decline in net profit margins, with a weighted average return on equity of 3.80% in 2022, down from 68.85% in 2021[27]. - The gross profit margin for erythritol products dropped to 10.50% in 2022 from 41.56% in 2021, reflecting a significant decline of 31.06%[57]. - The revenue from the food additive industry was CNY 655.82 million, accounting for 97.17% of total revenue, with a year-on-year decrease of 60.05%[81]. - The company's sales volume in the food additive industry decreased by 47.37% year-on-year, while production volume dropped by 44.08% due to intensified market competition and reduced orders from downstream customers[84]. Market Conditions - The sales revenue of the company's products declined due to economic downturn and weak consumer demand, particularly in the downstream beverage and dining sectors[4]. - The market price of erythritol significantly decreased, compressing the profit margins for industry players due to increased supply from new capacities and expansions by existing companies[4]. - The functional sugar industry, particularly erythritol, faced increased competition in 2022, leading to a supply surplus and a significant drop in prices, impacting profitability[43]. - The overall demand for functional sugars is expected to grow due to increasing consumer awareness of health and nutrition[45]. - The company operates in the functional sugar sector, focusing on erythritol production, which is expected to benefit from the growing health-conscious consumer trend[45]. Investment and R&D - The company invested in a wholly-owned R&D subsidiary to enhance its core technology competitiveness and expand its product range, including new products like stevia and hyaluronic acid[78]. - The company established a wholly-owned R&D subsidiary focused on high-end applications in synthetic biology, collaborating with multiple research institutions[71]. - The company aims to achieve a fermentation reaction cycle of no more than 24 hours and a yield of no less than 95% in glucose acid production[97]. - The company is developing a high-yield strain of yeast for erythritol production, targeting a yield of at least 50% using glucose as the substrate[97]. - The company has completed the development of alulose preparation technology, achieving a purity of over 95%[96]. Production and Supply Chain - The company benefits from a stable supply of raw materials, particularly starch derived from corn, which is abundant in its operational region[46]. - The company employs a "production based on orders" procurement model, maintaining a short inventory cycle for main raw materials and a longer cycle for auxiliary materials[51]. - The production model is customer order-oriented, ensuring timely delivery based on customer specifications and maintaining appropriate finished goods inventory levels[52]. - The company has improved the purity of erythritol extracted from mother liquor from below 50% to over 80% through innovative extraction techniques[68]. - Automation improvements have increased temperature control precision to 0.1°C, compared to the traditional manual control range of 3-5°C[69]. Strategic Initiatives - The company plans to launch a new small packaging brand "Yuan Sheng Tian" to expand its market reach from B2B to B2C, enhancing brand awareness and market influence[54]. - The company is focusing on expanding its retail presence by acquiring a 20% stake in PeiXue Biotechnology to enhance its market influence[79]. - The company aims to maintain its market leadership in erythritol while developing competitive functional sugars and expanding into specialized food, cosmetics, and drug delivery systems, driven by consumer demand for green and healthy products[129]. - The company plans to enhance its R&D capabilities by collaborating with leading food fermentation research institutions to improve product innovation and reduce reliance on a single product[131]. - The company is actively expanding its customer base by targeting small and medium enterprises to reduce reliance on major clients[140]. Governance and Compliance - The company maintains independent operations with complete control over its assets, personnel, finance, and business, ensuring no violations by the controlling shareholder[155]. - The company has established a performance evaluation and incentive mechanism for directors and senior management, aligning with its development status[150]. - The company adheres to strict internal audit procedures, enhancing governance and ensuring the achievement of operational goals[154]. - The company has independent financial accounting systems and decision-making capabilities, complying with accounting standards[157]. - The company has a transparent information disclosure system, ensuring fair access to information for all investors[152]. Shareholder and Dividend Information - The profit distribution plan approved by the board is to distribute a cash dividend of 7 RMB (including tax) for every 10 shares, based on a total of 202,325,700 shares[6]. - The total distributable profit for shareholders was CNY 833,753,971.65, which is the lower of the consolidated and parent company reports[198]. - The cash dividend represents 100% of the total profit distribution amount[195]. - The company strictly follows its profit distribution policy, ensuring clarity and compliance with relevant regulations during the dividend distribution process[193]. - The company distributed a cash dividend of 10.00 yuan per 10 shares, totaling 134,883,800.00 yuan, and increased its share capital by 67,441,900 shares through a capital reserve conversion[192].

Financial Performance - The company's revenue for Q1 2023 was ¥116,276,458.04, a decrease of 57.35% compared to ¥272,598,107.02 in the same period last year[4] - Net profit attributable to shareholders was ¥7,808,194.59, down 87.56% from ¥62,765,994.16 year-on-year[4] - Basic and diluted earnings per share fell by 92.16%, from ¥0.51 to ¥0.04[4] - The total operating revenue for Q1 2023 was ¥116,276,458.04, a decrease of 57.3% compared to ¥272,598,107.02 in the same period last year[25] - The net profit for Q1 2023 was ¥7,808,194.59, a decline of 87.5% compared to ¥62,765,994.16 in Q1 2022[27] Cash Flow - The net cash flow from operating activities decreased by 87.17%, from ¥20,443,976.73 to ¥2,622,930.65[4] - The net cash flow from operating activities for the first quarter was ¥2,622,930.65, a decrease of 87.2% compared to ¥20,443,976.73 in the previous period[31] - Total cash inflow from operating activities was ¥143,143,501.00, down from ¥312,922,891.80 in the previous period[30] - Cash received from sales of goods and services was ¥125,411,624.65, a decline from ¥285,616,286.62 in the previous period[30] - The ending balance of cash and cash equivalents was ¥142,378,891.60, down from ¥267,134,010.23 in the previous period[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,858,759,156.00, a slight decrease of 0.23% from the previous year[4] - The total liabilities for Q1 2023 were ¥230,174,915.00, a decrease from ¥249,143,294.88 in the same period last year[24] - The company's long-term equity investments amounted to ¥59,706,991.87, a slight decrease from ¥60,156,008.48 in the previous year[24] Income and Expenses - The total operating costs for Q1 2023 were ¥135,685,668.54, down 37.1% from ¥215,835,919.52 in Q1 2022[25] - Research and development expenses for Q1 2023 were ¥11,788,523.18, an increase of 15.4% compared to ¥10,219,983.55 in Q1 2022[25] - Other income increased by 1,413.01%, mainly due to government subsidies received during the reporting period[8] - The company reported a significant increase in other income to ¥506,858.66 from ¥33,500.01 in the previous year[27] Shareholder Information - The total number of shares held by major shareholders includes 12,852,000 shares by Liu Xi'an and 5,399,970 shares by Shandong Kexin Venture Capital Co., Ltd[11] - The company reported a total of 92,946,000 restricted shares held by Nie Zaijian, with the release date set for August 10, 2025[13] - The company has 24,780,000 shares released from restrictions as of February 10, 2023, indicating a significant liquidity event for shareholders[14] - The total number of shares held by the top 10 unrestricted shareholders includes 2,681,475 shares by Wang Shen and 2,653,995 shares by Wang Meihua[11] Fund Management - The company plans to use RMB 790 million of the raised funds to permanently supplement its working capital starting from March 2, 2023[16] - The company approved the use of up to RMB 2.4 billion of temporarily idle raised funds for cash management, effective for 12 months from the approval date[17] - The company intends to use up to RMB 2.2 billion of temporarily idle self-owned funds for cash management, also effective for 12 months from the approval date[18] Investment Activities - Total cash inflow from investment activities was ¥10,416,708.33, significantly up from ¥477,900.00 in the previous period[31] - The net cash flow from investment activities was -¥328,183,999.71, compared to -¥3,562,704,045.45 in the previous period, indicating a reduction in cash outflow[31] Share Reduction Plans - The company’s major shareholder, Shandong Luxin Qisheng Investment Management Co., plans to reduce its holdings by up to 12.14 million shares, representing 6% of the total share capital[20] - The chairman of the supervisory board, Cui Zhenqian, completed a share reduction plan, selling up to 170,625 shares, which is 0.0843% of the total share capital[19] Other Information - The company did not engage in any financing activities during the reporting period, resulting in a 100% decrease in cash flow from financing activities[8] - The company did not report any new product developments or market expansions during this quarter[32]

证券代码：301206 证券简称：三元生物 公告编号：2023-031 2023 年 4 月 27 日 特此公告。 山东三元生物科技股份有限公司 山东三元生物科技股份有限公司 关于举行 2022 年度网上业绩说明会的公告 董事会 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日在 巨潮咨询网（www.cninfo.com.cn）上披露了公司《2022 年年度报告》及《2022 年年度报告摘要》。为便于广大投资者进一步了解公司生产经营、财务状况、战 略规划等情况，公司定于 2023 年 5 月 12 日（星期五）下午 15:00-17:00 在深圳 证券交易所"互动易"平台举行 2022 年度网上业绩说明会，就投资者关心的问 题进行交流。本次业绩说明会将采用网络远程方式举行，投资者可登录深圳证券 交易所"互动易"平台（http://irm.cninfo.com.cn）进入"云访谈"栏目参与本次 业绩说明会。 出席本次业绩说明会人员有：董事长、代行董事会秘书聂在建先生，总经理 程保华先 ...

证券代码：301206 证券简称：三元生物 三元生物上市公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |-------------------|------------------------------------------------|----------------------------------------------------------------| | | √特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 | □新闻发布会 □路演活动 | | | 类别 | □现场参观 □电话会议 | | | | □其他： （请文字说明其他活动内容） | | | 参与单位名称 | 华夏基金及其邀请人员 6 | 人；南方基金及其邀请人员 5 人 | | 及人员姓名 | | | | 时间 | 2022 年 4 月 29 日 | | | 地点 | 网络会议 | | | 公司接待人员 姓名 | 代行董事会秘书聂在建先生、证券部工作人员 | | | | Q&A | 交流问题纪要（口头交流内容表述可能存在误差，如与正式公告内 ...